For the quarter ending 2025-09-30, ESPR had $6,386K increase in cash & cash equivalents over the period. -$4,286K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -31,333 | -53,180 |
| Non-cash loss on extinguishment of debt | 0 | 0 |
| Non-cash royalty revenue | 16,359 | 24,061 |
| Paid-in-kind interest on long-term debt | 4,580 | 4,406 |
| Depreciation expense | 26 | 53 |
| Amortization of debt issuance costs and discounts | 847 | 1,519 |
| Non-cash interest expense related to the revenue interest liability | 0 | 0 |
| Non-cash interest expense related to the royalty sale liability | 14,637 | 26,363 |
| Stock-based compensation expense | 2,349 | 5,134 |
| Accounts receivable | 11,234 | 27,604 |
| Prepaids and other assets | 6,176 | 15,718 |
| Deferred revenue | 8,366 | 13,795 |
| Inventories | -5,927 | 19,975 |
| Other long-term liabilities | 0 | 7,436 |
| Accounts payable | 2,901 | 30,462 |
| Other accrued liabilities | 21,183 | -2,680 |
| Net cash (used in) provided by operating activities | -4,286 | -54,050 |
| Purchase of property and equipment | 0 | 0 |
| Net cash (used in) investing activities | 0 | 0 |
| Payments on revenue interest liability | 0 | 0 |
| Repurchase of revenue interest liability | 0 | 0 |
| Payment of royalty sale liability issuance costs | 0 | - |
| Proceeds from royalty sale liability | 0 | 0 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock from atm program, net of issuance costs | 10,531 | 2,850 |
| Proceeds from exercise of common stock options | 141 | 0 |
| Proceeds from exercise of warrants, net of issuance costs | 0 | 0 |
| Payment of issuance costs | 0 | 7,500 |
| Net cash provided by financing activities | 10,672 | -4,650 |
| Net (decrease) increase in cash and cash equivalents | 6,386 | -58,700 |
| Cash and cash equivalents at beginning of period | 144,761 | - |
| Cash and cash equivalents at end of period | 92,447 | - |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)